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T he development of the IIeartSaver Ventricular As- sist Device (VAD) (Worhllteart Corporation, Ot- 
tawa, Canada) was begun in 1984 at the University of 
Ottawa Heart Institute under tile direction of Dr Wil- 
bert Keon with the l,rel,aration of a grant proposal 
outlining the design of a totally iml,lantable , lectrohy- 
draulic VAD. The components of tile device, including 
the unified pump (containing tile blood sac, motor, and 
volume displacement chamber), the internal battery 
and external power supply, the transcutaneous energy, 
and signal system (TESS), were devcloped separately 
by specialized groups over the next 6 years. 1-9 
With a primary design objective to have an intratho- 
racic positioning of the device, planning for the uhi- 
mate imi, lantation teelmique of the VAD in lmmans 
has occurred during the development s ages of the 
project, w,l~ At the same time, an ahernative implanta- 
tion technique was developed for use in tile calf model 
to allow for animal studies, wlfich is described else- 
where. 12 The rationale for an intrathoracic placement 
was to allow the inflow anti outflow cannulae length to 
be minimized to reduce risk of thromboeml~olism, to 
provide a neutral pressure ill which tile volume dis- 
placement chamber wouhl reside, and to minimize com- 
pression of any internal organ wlfile reducing the length 
of incisions and amount of dissection eeded for im- 
plantation. Placement of the TESS secondary coil and 
internal mttery was to be done using standard tech- 
nique developed for pacemakers and implantable deft- 
brillators. 
There have been concerns expressed by some over 
the intrathoracic location with fear of potential com- 
pression of the lung. However, it was felt that the 
dilated, failing heart would create a potential space 
that would be left once the heart was decompressed 
by tile VAD and that the anterior compression of the 
lung would be minimal considering that most of the 
left lung resides infero-posteriorly. In addition, a 
potential space exists between the chest wall and 
diaphragm antero-laterally to the heart that is rou- 
tinely developed for implantation of the current gen- 
eration of VADs. This space couhl be developed for 
the I leartSaver device and tailored for ideal posi- 
tioning with the decompressed heart. Displacement 
of abdominal contents wouhl be minimized by this 
technique, which has created some problems with 
other devices in terms of early satiety and limitations 
i l l  n loven lent .  
Numerous hunmu cadaver fit trials have been per- 
formed with tile different configurations of the device 
as it was developed, l~ At tile time of this writing, the 
HeartSaver VAD was undergoing final animal testing 
before regulatory approval, and, to date, no human 
has been implanted with the device. 
Device Descr ipt ion 
The resnhant HeartSaver VAD consists of 3 implant- 
able components: the HeartSaver VAD refit, the inter- 
nal battery and the internal transeutaneous energy and 
signal system (TESS), as well as connecting cables (Fig 
I). The VAD unit uses electrohydraulic a utation and 
combines the 1,1ood sac, volume displacement chamber 
(VDC) (containing silicone oil), electrohydraulic axial 
flow pump, and control electronics into a single unit 
capable of being implanted into the thoracic space. 
Power to the device may be from external batteries or 
an internal ithium ion battery that gives patients the 
potential to be disconnected from the external Imttery 
for 45 to 60 minutes, thereby allowing patients the 
freedom to move, shower, and perform unrestricted 
physical activities. Tile external controller may be con- 
nected to a remote monitor that may communicate by 
telel,hone, internet, or satellite to other centers for 
remote assessment of device function. 
Anatomic Considerat ions 
With each of the 3 components, there are consider- 
ations for anatomic placement of this device. The first 
is the positioning of the TESS primary coil. It may be 
placed ill 1 of 3 locations in order of preference: axil- 
lary, pectoral, or on the lower anterior chest. Because 
of its pear shape and length of 14.8 cm, it would be 
advantageous to identify tile position of tile TESS pre- 
operatively to optimize its location in each individual 
patient. 
Tile second consideration is for the position of the 
internal battery. This shouhl likely be placed in the 
preperitoncal space below the rectus muscle similar to 
tile position of the early ICDs. However, if the lmtient 
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seems to have a gellcrotls alnount of sul}cutallCOUS tis- 
sue, then a supra-rectus heath position nmy l)e con- 
sidered, which shouhl facilitate the rcl,laccmcnt of the 
battery if needed in tile fi~ture. 
The third consideration is the intrathoracic posi- 
tion of the HeartSaver  l)lood I)Uml ). The device was 
designed to be in the left l)leural cavity for reasons 
mentioned above. However,  tile exact position will 
depend on a numl)cr of factors: (1) chest width, (2) 
angulation of the chest wall lateral to the sternum in 
the horizontal axis, (3) posit ion of the left vcntr icular 
apcx in the lmricardium, (4) amount of disl)laccmcnt 
of the right ventricle, and (5) length and angulation 
of inflow cannula chosen for use. 
FIG I. IleartSaver VAD system COml)oncnts including (left to right) (1) Transcutancous Energy and Signal System, (2) blood 
imml) consisting of a volunle displaccnmnt cllambcr, Illood sac, motor, and silicone hydraulic tluid, and (3) lithiunl ion internal 
battery. 
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1A Axillary location of TESS. 1B Pectoral ocation of TESS. The TESS pocket is niade first. A 9 cm horizontal incision 
is made in the axilla, pectoral or lower chest re ,on and carried down through siibcutaneous tissue to pre-muscular fascia. A 
subcutaneous pocket of appropriate size (8.75 • 14.5 cm) to accommodate the TESS is nlade using provided sterile models 
as guides. 
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2 Internal battery with connector may be positioned either horizontally or vertically in a supra- or sub-rectus heath 
position. A median sternotomy skin incision is made anti carried down to midway between tile xiphistcrnnm and umbilicus. 
A preperitoncal pocket is made by incising tile anterior ectus sheath jiist lateral to the linca alba and lifting the rectus sheath 
anteriorly. A plane above the posterior rectus sheath is made to accommodate the internal battery model in either a horizontal 
or longitudinal orientation, depending on preoperative measurements. 
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3 Intrathoraeic 1)lacement of I IcarlSaver VAD ill tile left lllcural space with inflow and outflow cannulae connectell to left 
ventricle and aorta, respectively. Tile sternum is divided, and tile pericardiulu is Ollcned as far right as possible to create a 
pericardial tlap that can be nsed to cover the ontflow cannula at tile end of the procedure. The left plenral cavity is opened 
to allow positiolfing of the VAD model. I f  needed, a plane between the left anterior chest anti diaphragm can be created to allow 
for the inferior displacelnent of the VAD. An appropriate inflow and outllow canmda are selected to Ol)tilnize VAD l)lacclncnt 
to prevent excessive rightward displacmcnt of the heart. 
Once the VAD position is dctcrluincd, the TESS and internal battery are ilnplantcd with their cables and connectors llrought 
through to tile location of the VAD using sullcutancous tnnnelers provided with the implant kit. This is done before 
hcparinization of the patient. 
The cannulae are implanted with the patient anticoagulatcd with hcparin and placed on cardiolmhnonary bypass to 
facilitate this part of tile procedure. A sidebiting clamp is placed on tile left side of the ascending aorta and an aortotomy is 
made. The outflow graft is cut to an appropriate length and anastolnosed to the aorta. The lleart is SUllportcd out of the 
pericardium with sponges, and a site for left vcntricular cannulation is determined based on VAD lnodel positioning. 
Approximately 10 interrupted pledgetcd sutures of 1 or 2 braided material are lllaccd around tile apex of tile left ventricle or 
just adjacent o it. A vcntricnlotolny is made with a punch or scalpel and the cored apex is sent for histolo~c exanfination. 
The left ventricle is inspected internally to ensure the absence of thromllns or potential ollstruction to inilow. The cannula is 
placed into the ventricle, anti sutures are bronght through tile sewing ring and tied. 
The I IeartSavcr VAD is placed into tile chest in its predetermined position, anll tile cannulae are attached to tile appropriate 
ports after filling tile blood sac with heparinizcd saline or albnmin. Tile gland nuts are left loose to facilitate de-airing. A 
catheter is placed into the outflow graft, and suction is allplied with the outflow graft occlullcd distally. 
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4 Final configuration ~ith HeartSaver VAD in left chest connected to TESS and internal battery. Tile TESS and internal 
battery are connected to the HeartSaver VAD. Tile connectors are aligned and screwed together with tools provided in tile 
implant kit. The clinical engineer/perfusionist performs a check of the appropriate powering and comnmnications with the 
device to ensure proper connection and ali~lment between components (TESS and battery). Tile VAD is actuated with single 
beats and de-aired with some movement of the VAD to displace air. 
Once de-airing is complete, the VAD is turned on to pump at a fixed rate of 60 bpm anti the patient is slowly weaned off 
cardiopulmonary b pass with tile outflow graft on continuous venting and suction to remove any residual air. When stable, 
tile VAD can be turned on full-fill/filll-eject mode. 
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5 Patient after cliest closure ~dth TESS primary coil in place and 3 chest tubes draining left chest and pericardial space. 
Tile chest, abdominal, and TESS pocket incisions are all closed ~itll standard techniques used ill tile institution. Tile priinary 
coil of tile TESS is placed and secured with a harness over tile secondary coil. 
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Postoperat ive Course and Follow-Up 
Patients will remain in tim intensive care unit until 
stable. Tim following most common medications can be 
anticipated: 
Inotropic agents for right ventricular snpport, whicll 
can nsually be weaned slowly over the first few postop- 
erative days 
Anticoa~dation will start approximately 8 lmurs af- 
ter surgery provided cllest tube losses are less tilan 50 
mL/h. This will include intravenous heparin to main- 
tain tim partial thromboplastin time in tim range of 60 
to 90, followed by clopedigrel, 75 mg per day, be~nning 
on day 1. Hcparin can be changed to coumadin when 
the patient is stable and ambulatory with the Interna- 
tional Normalized Ratio target between 2.5 to 3.5 
Patients will undergo routine cardiac relmbilitation 
while in tim hospital. Device fimction will be closely 
monitored with attention paid to pump filling and re- 
sponse to exercise. Preparations for discharge will in- 
clude device education by a VAD nurse or clinical 
engineer. Major issues will lie to determine comfortable 
fit of the primary coil in the axilla/pectoral rea with 
snl)port api)liances , tim adequacy of communication 
and power transfer with the positioning of the subcu- 
tancous TESS coil, the proper opcration of the internal 
battery as a stand-alone power supply, the fnnction of 
the alarms and patient awareness of appropriate ac- 
tions if an alarm sounds, and the outfitting of the 
patient's home for a battery cllargcr. Follow-up will 1)e 
done through the heart failure/VAD clinic on a regular 
basis to cnsnre i)roper device flmction anti patient 
stains. 
Conlmenls 
The HeartSaver VAD is a pnlsatile, totally implantalfle 
VAD that shouhl have the benefit of no pereutancous 
connections, wlfieh should translate into fewer infec- 
tions compared with older- generation VADs. The im- 
portance of pnlsatility long-term remains to be seen, 
bnt the high- volume, low-velocity pnmlfing action may 
have its benefits compared with the lower-volume, high- 
velocity output of nonlmlsatile VADs. Comlmred with 
other totally implantablc pulsatilc systems, the vohnne 
displacement chamber design prevents the need for 
periodic refilling, and tim system components are more 
compact. The power supplies are desi~md to allow a 
high degree of mobility without restricting daily activ- 
ities. The VAD allows for tile heart to be left in situ, 
thereby resuhing in a permanent 1)ackup ill ease of 
device failure, which is an advantage compared x~ith 
total artificial hearts. 
The HeartSaver VAD has been under development 
since 1989 and is currently undergoing formal animal 
testing before regulatory approval for human use. The 
device lms been proven to be reliable in in vitro testing 
and preliminary in vivo experiments but requires fiw- 
ther optimization. It is hoped tlmt the advantages of 
this system are proven in the initial clinical trials, 
which should be underway once optimization is com- 
plete. 
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